Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (ENDOSafe)
Comparing the Safety and Efficacy in the Use of Dienogest, Leuprolide Acetate, DMPA and Combined Oral Contraceptive Pills (Microgynon) on Endometriosis Patients After Conservative Surgery
The goal of this clinical trial is to compare safety and efficacy in endometriosis patient after conservative surgery. The main question[s] it aims to answer are:
- Health-related quality of life (HRQoL)
- VAS score
- Beta estradiol
- TNF Alpha
- Adnexal mass recurrence
Participants will be randomized into 4 groups, each group will receive:
- Leuprolide Acetate injection/month
- Dienogest 2 mg/day
- COC (mycrogynon)/day
- DMPA injection 150mg/month Researcher will compare the efficacy and safety in the assigned group.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Beta estradiol level is measured in the serum, before and after treatment
- TNF alpha is measured in the serum, before and after treatment
- Evaluation of HRQoL using the Endometriosis Health Profile-30 (EHP-30)
- VAS score will be recorded before and after treatment
- Adnexal massa recurrence evaluation using USG
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Central Java
-
Semarang, Central Java, Indonesia, 50244
- Kariadi Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patient post surgical removal of endometriosis cyst Willing to participate
Exclusion Criteria:
- Use of any hormonal therapy for endometriosis within the previous 16 weeks.
- History of severe adverse drug reactions or hypersensitivity to steroid hormones.
- Failure of previous treatment with COC, DMPA used in this study.
- There are contraindications to the use of Leuprolide Acetate, COC, DMPA or Dienogest, such as a history or complications of thrombosis/embolism, stroke, Diabetes Mellitus, liver cirrhosis or other liver function disorders, breast, ovarian and endometrial malignancies.
- Smoker.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Leuprolide Acetate
Leuprolide Acetate, brand name Tapros 3.75 mg, injected intramuscularly every month for 3 months
|
Drug is injected intramuscularly on the buttock
Other Names:
|
|
Experimental: Dienogest
Dienogest 2 mg, brand name Nelandoz 2mg, administered orally, every day for 3 months
|
Drug is administered orally at the same time every day
Other Names:
|
|
Experimental: Depot medroxyprogesterone acetate
Depot medroxyprogesterone acetate, brand name Depo Provera 150mg/ml, injected intramuscularly, every month for 3 months
|
Drug is injected intramuscularly on the buttock
Other Names:
|
|
Experimental: Combined Oral Contraceptive
Levonogestrel 150 mcg + etinilestradiol 30 mcg, brand name Mycrogynon, administered orally, every day for 3 months
|
Drug is administered orally at the same time every day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
beta estradiol level
Time Frame: 0 and 12 weeks of treatment
|
Measuring beta estradiol level on the serum
|
0 and 12 weeks of treatment
|
|
TNF alpha level
Time Frame: 0 and 12 weeks of treatment
|
Measuring TNF alpha level on the serum
|
0 and 12 weeks of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAS score
Time Frame: 0 and 12 weeks of treatment
|
Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum.
0 means "no pain" and 10 means"worst pain
|
0 and 12 weeks of treatment
|
|
health-related quality of life (HRQoL)
Time Frame: 0 and 12 weeks of treatment
|
Endometriosis Health Profile-30 (EHP-30).
It consists of 30 items to which respondents can choose between the answers: Never (0); Rarely (1), Sometimes (2); Often (3); and Always (4).
The 30 items are divided into five subscales covering 'pain', 'control and powerlessness', 'social support', 'emotional wellbeing' and 'self-image'.
Each scale is standardized on a scale from 0 to 100, with lower scores indicating better QoL
|
0 and 12 weeks of treatment
|
|
Mass recurrence
Time Frame: 0 and 12 weeks of treatment
|
Evaluate the adnexal mass using Ultrasound after completing treatment
|
0 and 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yuli Trisetiyono, SpOG (K), Diponegoro University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Endometriosis
- Contraceptive Agents, Hormonal
- Antineoplastic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Reproductive Control Agents
- Hormone Antagonists
- Fertility Agents, Female
- Fertility Agents
- Contraceptive Agents, Female
- Estrogens
- Contraceptives, Oral, Hormonal
- Contraceptives, Oral, Synthetic
- Contraceptive Agents, Male
- Leuprolide
- Medroxyprogesterone Acetate
- Medroxyprogesterone
- Contraceptive Agents
- Ethinyl Estradiol
- Contraceptives, Oral
- Contraceptives, Oral, Combined
- Dienogest
Other Study ID Numbers
Other Study ID Numbers
- 00000088
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.